Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab) in JASMINE Study for Non-Hodgkin’s Lymphoma

Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab) in JASMINE Study for Non-Hodgkin's Lymphoma

Shots:

  • The JASMINE study involves assessing of ABP 798 vs its reference product, Rituximab at a dose of 375 mg/m2 (IV, qw) for 4wks. followed by dosing at weeks 12 and 20 in 256 patients with non-Hodgkin’s lymphoma
  • The JASMINE study results demonstrated bio-similarity data in its 1EPs i.e, ORR @28wks. and clinical equivalence to Rituxan. Additionally, the companies conducted a clinical study of ABP 798 in mod. to sev. RA patients resulting in clinical equivalence & pharmacokinetic similarity
  • ABP 798 is an anti-CD20 mAb having the same amino acid sequence as the reference product, Rituxan. In Dec 2011, Amgen and Allergan entered into a WW collaboration to develop & commercialize four oncology antibody biosimilar therapies

Click here to­ read full press release/ article | Ref: Amgen | Image: Behance